CLGN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	1 227.00
Average Volume	7 577.00
Market Cap	59.56M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.350 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.39
ATR14	$0.0350 (0.67%)

Collplant Biotechnologies Correlation

10 Most Positive Correlations
NETE	0.965
CPTN	0.964
QRTEA	0.964
PRCH	0.96
RAVN	0.953
PRAX	0.953
AADI	0.949
CDNA	0.949
CYCC	0.948
ICCC	0.948

10 Most Negative Correlations
PAIC	-0.973
SVAC	-0.948
SGEN	-0.939
TIG	-0.937
ORTX	-0.925
CCRC	-0.914
PPYAU	-0.912
DNUT	-0.905
TLGT	-0.903
BTBD	-0.902

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Collplant Biotechnologies Financials

Annual	2023
Revenue:	$10.96M
Gross Profit:	$7.87M (71.78 %)
EPS:	$-0.620

Q4	2023
Revenue:	$299 000
Gross Profit:	$-758 000 (-253.51 %)
EPS:	$-0.410

Q3	2023
Revenue:	$43 000.00
Gross Profit:	$-235 000 (-546.51 %)
EPS:	$-0.380

Q2	2023
Revenue:	$10.18M
Gross Profit:	$9.57M (93.96 %)
EPS:	$0.510

Financial Reports:

No articles found.

Collplant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.